Patient Enrollment

Axsome Therapeutics Commences Late-Stage Migraine Study

Stoke Therapeutics Commences Initial-Stage Optic Nerve Disorder Study

Annovis Shares Gain As Late-Stage Parkinson's Disease Study Takes-off

Stoke Therapeutics Commences Initial-Stage Optic Nerve Disorder Study

Annovis Shares Gain As Late-Stage Parkinson's Disease Study Takes-off

Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off

BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off

Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off

BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off

Palisade Bio Shares Drop Following Commencement Of Late-Stage Return Of Bowel Study

Anixa Initiates Patient Dosing in Initial-Stage Ovarian Cancer Study

Patient Enrollment Recent News

Virios Therapeutics Commences Mid-Stage Long-COVID Study

Virios Therapeutics (Nasdaq: VIRI) has initiated patient dosing in its exploratory Long-COVID trial evaluating IMC-2 (valacyclovir + celecoxib).

Avalo Therapeutics' Shares Climb Following Patient Dosing in Immunodeficiency Disorder Study

Avalo Therapeutics (NASDAQ: AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER).

Kymera Therapeutics Commences Initial-Stage Oncology Trials

Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.

Apellis Begins Paitent Dosing In Late-Stage Study Of Rare Kidney Disease Candidate

Apellis Pharmaceuticals (NASDAQ: APLS) has dosed first patient in the VALIANT Phase 3 clinical study of its drug candidate Pegcetacoplan for primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G), two rare and debilitating kidney diseases with similar underlyin

Moderna Commences Late-stage Study of Flu Vaccine Candidate

Moderna, Inc. (NASDAQ: MRNA) today announced Initiation of Patient dosing in the phase 3 clinical study of its seasonal influenza vaccine candidate mRNA-1010 for patients with influenza.